期刊
ISCIENCE
卷 24, 期 9, 页码 -出版社
CELL PRESS
DOI: 10.1016/j.isci.2021.103078
关键词
-
资金
- Patient-Centered Outcomes Research Institute (PCORI) Award [MS-1511-33196]
- Swedish Medical Research council [2017-03054]
- Swedish Brain Foundation, NEURO Sweden
- Region Stockholm
- Knut and Alice Wallenberg foundation
- Erling-Persson family foundation
- Petrus och Augusta Hedlunds Stiftelse
- Swedish Research Council [2017-03054] Funding Source: Swedish Research Council
Research showed that almost all seropositive patients and 17.9% of seronegative patients on B cell depleting therapies developed anti-SARS-CoV-2 T cell memory, with functional similarity to controls. Following vaccination, vaccine-specific humoral memory was impaired, but all patients developed a specific T cell response.
B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome virus-2 (SARS-CoV-2) has raised concerns with the coronavirus disease 2019 (COVID-19) pandemic. We here evaluated the frequency of COVID-19-like symptoms and determined immunological responses in participants of an observational trial comprising several multiple sclerosis disease modulatory drugs (COMBAT-MS; NCT03193866) and in eleven patients after vaccination, with a focus on BCDT. Almost all seropositive and 17.9% of seronegative patients on BCDT, enriched for a history of COVID-19-like symptoms, developed anti-SARS-CoV-2 T cell memory, and T cells displayed functional similarity to controls producing IFN-gamma and TNF. Following vaccination, vaccine-specific humoral memory was impaired, while all patients developed a specific T cell response. These results indicate that BCDTs do not abrogate SARS-CoV-2 cellular memory and provide a possible explanation as to why the majority of patients on BCDTs recover from COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据